Palisade Bio Soars 13% on Clinical Trial Progress

Palisade Bio's stock surged by 12.99% in pre-market trading on July 22, 2025, marking a significant rise that has caught the attention of investors and analysts alike.

Palisade Bio has made substantial progress in its clinical trials, having initiated a Phase 1b multiple-ascending dose study in patients with ulcerative colitis following the successful completion of Phase 1a. This development is a crucial step forward in the company's efforts to bring novel peptide-based therapeutics to market.

The company's recent earnings report for Q2 2025 highlights its focus on the discovery and development of innovative treatments, further solidifying its position as a key player in the biotechnology sector. The report underscores Palisade Bio's commitment to advancing its pipeline and delivering value to shareholders.